References
- Allende, D. and McIntosh, T.J. (2003) “Lipopolysaccharides in bacterial membranes act like cholesterol in eukaryotic plasma membranes in providing protection against melittin-induced bilayer lysis”, Biochemistry 42, 1101–1108.
- Almeida, A.J. and Alpar, H.O. (1996) “Nasal delivery of vaccines”, J. Drug Target 3, 455–467.
- Alpar, H.O., Bowen, J.C. and Brown, M.R.W. (1992) “Effectiveness of Liposomes as Adjuvants of Orally and Nasally Administered Tetanus Toxoid”, Int. J. Pharm. 88, 335–344.
- Alpar, H.O., Eyles, J.E., Williamson, E.D. and Somavarapu, S. (2001) “Intranasal vaccination against plague, tetanus and diphtheria”, Adv. Drug Delivery Rev. 51, 173–201.
- Artursson, P. and Magnusson, C. (1990) “Epithelial transport of drugs in cell culture. II: effect of extracellular calcium concentration on the paracellular transport of drugs of different lipophilicities across monolayers of intestinal epithelial (Caco-2) cells”, J. Pharm. Sci. 79, 595–600.
- Dunn, R.D., Weston, K.M., Longhurst, T.J., Lilley, G.G., Rivett, D.E., Hudson, P.J. and Raison, R.L. (1996) “Antigen binding and cytotoxic properties of a recombinant immunotoxin incorporating the lytic peptide, melittin”, Immunotechnology 2, 229–240.
- Eyles, J.E., Bramwell, V.W., Williamson, E.D. and Alpar, H.O. (2001) “Microsphere translocation and immunopotentiation in systemic tissues following intranasal administration”, Vaccine 19, 4732-4742. Galazka, A. (2000) “Implications of the diphtheria epidemic in the Former Soviet Union for immunization programs”, J. Infect Dis. 181, S244–S248.
- Hilsted, J., Madsbad, S., Hvidberg, A., Rasmussen, M.H., Krarup, T., Ipsen, H., Hansen, B., Pedersen, M., Djurup, R. and Oxenboll, B. (1995) “Intranasal insulin therapy: the clinical realities”, Diabeto- logia 38, 680–684.
- Kortt, A. (1999) http://www.albertabeekeepers.org/Articles/1099_1.html Illum, L., et al. (1998) “Bioadhesive formulations for nasal peptide delivery”, In: Mathiowitz, E., ed, Drug Delivery Issues in Fundamentals, Novel Approaches and Development (Marcel Dekker, New York).
- Illum, L. (2002) “Nasal drug delivery: new developments and strategies”, Drug Discov. Today 7, 1184–1189.
- Liu, P., Davis, P., Liu, H. and Krishnan, T.R. (1999) “Evaluation of cytotoxicity and absorption enhancing effects of melittin—a novel absorption enhancer”, Eur. J. Pharm. Biopharm. 48, 85–87.
- Ourth, D.D. (1974) “Neutralization of diphtheria toxin by human immunoglobulin classes and subunits”, Immunochemistry 11, 223–225.
- Ryan, E.J., McNeela, E., Pizza, M., Rappuoli, R., O’Neill, L. and Mills, K.H. (2000) “Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: distinct pro- and anti- inflammatory effects of the nontoxic AB complex and the enzyme activity”, J. Immunol. 165, 5750–5759.
- Saini, S.S., Chopra, A.K. and Peterson, J.W. (1999) “Melittin activates endogenous phospholipase D during cytolysis of human monocytic leukemia cells”, Toxicon 37, 1605–1619.
- Tomita, M., Shiga, M., Hayashi, M. and Awazu, S. (1988) “Enhancement of colonic drug absorption by the paracellular permeation route”, Pharm. Res. 5, 341–346.